Overview

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Status:
Recruiting

Trial end date:
2028-05-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry [IHC]2+/in situ hybridization [ISH]- and IHC 1+) population.

Phase:

Phase 3

Details

Lead Sponsor:

DualityBio Inc.

Collaborator:

BioNTech SE

Treatments:

Albumin-Bound Paclitaxel
Capecitabine
Paclitaxel